|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0013216,
umls-concept:C0027498,
umls-concept:C0030705,
umls-concept:C0035820,
umls-concept:C0061851,
umls-concept:C0205421,
umls-concept:C0209210,
umls-concept:C0332162,
umls-concept:C1881878,
umls-concept:C2587213,
umls-concept:C2936526
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1997-6-5
|
|
pubmed:abstractText |
5-HT3 antagonists are effective in reducing the acute nausea and vomiting caused by cancer chemotherapy. However, it is not clear whether continuing these agents beyond twenty four hours is useful in controlling emesis on days two to seven after chemotherapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
pubmed-author:ChinCC,
pubmed-author:DempseyEE,
pubmed-author:GuevinR MRM,
pubmed-author:HainsworthJJ,
pubmed-author:HoskinsPP,
pubmed-author:KrookJ EJE,
pubmed-author:LoftersW SWS,
pubmed-author:MoquinJ PJP,
pubmed-author:NavaraJJ,
pubmed-author:PalmerMM,
pubmed-author:PaterJ LJL,
pubmed-author:VermaSS,
pubmed-author:WaldeDD,
pubmed-author:WilsonKK,
pubmed-author:ZehEE
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
8
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
181-5
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
|
|
pubmed:year |
1997
|
|
pubmed:articleTitle |
The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
|
|
pubmed:affiliation |
NCIC Clinical Trials Group, Queen's University, Kingston.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
